Skip to main content

What Regeneron's Quarter ended Sep 30, 2026 10-Q says: 2 signals

Regeneron filed its latest 10-Q with the SEC on Oct 30, 2026. It discusses compliance burden and major contract win.

Public (REGN)Biotechnology Research10,000+ employeesregeneron.comLinkedIn

Get Regeneron's live signals in Claude or ChatGPT, or by API

AskWhat changed at Regeneron this week? Use Autobound signals for regeneron.com.
Filed
Oct 30, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
9

Source: Autobound Signal API · 93 signals tracked for Regeneron · updated

10-Q · latest 8

What Regeneron's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 2 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Jun 30, 2026

    Filed · 2 signals

    SEC EDGAR
  3. 10-Q · Quarter ended Mar 31, 2026

    Filed · 5 signals

    SEC EDGAR

Showing 8 of 9 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Regeneron earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Expanded Sanofi alliance adds four next-gen antibodies with $1B upfrontRegeneron expanded its long-standing collaboration with Sanofi to advance four next-generation long-acting antibodies and bispecifics targeting type 2 inflammation pathways. Regeneron receives a $1 billion upfront payment in Q4 2026, with development costs and global profits split 50/50. This creates major opportunities for vendors supporting large-scale co-development and clinical trial...
Total revenue up 36% with EPS growth of 70%Regeneron delivered its third consecutive quarter of double-digit top and bottom-line growth, with total revenue rising 36% year-over-year. Non-GAAP diluted net income per share grew 70% to $20.07 on net income of $2.2 billion, driven by strength in core commercial franchises.
Differentiating NASH CIDEB siRNA mechanism against Madrigal and GLP-1sRegeneron highlighted that its CIDEB siRNA program directly targets a genetic driver of NASH, achieving 70% average liver fat reduction in 12 weeks. Management contrasted this direct mechanism against indirect metabolic therapies like Madrigal's agent and GLP-1 agonists such as semaglutide. Differentiated efficacy without requiring body weight reduction is positioned as a primary competitive...
Advance multiple registrational trials driving mid-teens 2027 R&D growthRegeneron plans to advance nearly 15 Phase III trials across multiple therapeutic areas in 2027, expecting R&D expense to grow by a mid-teens percentage over 2026. The clinical acceleration spans myeloma, anticoagulation, obesity, POTS, and NASH. This sharp rise in clinical development spend creates opportunities for contract research organizations, diagnostic providers, and clinical trial...
BARDA contract to supply Inmazeb doses through 2031Regeneron secured a new agreement with the Biomedical Advanced Research and Development Authority (BARDA) to supply additional treatment doses of Inmazeb to the U.S. government from late 2027 through 2031. Deliveries under the new contract will begin in late 2027, resulting in zero expected revenue from Inmazeb in Q4 2026. This multi-year federal commitment reinforces production requirements...
In-licensed olatorepatide from Hansoh advancing into global phase 3Regeneron is advancing global development of olatorepatide, a dual GLP-1/GIP receptor agonist in-licensed from partner Hansoh. The company plans to initiate registrational trials combining the asset with Praluent to treat obesity with dyslipidemia. This supplier and licensing partner arrangement drives specialized formulation and manufacturing procurement for combination regimens.

Signal API · MCP

Track Regeneron with the Signal API

One POST /v1/companies/enrich call with regeneron.com returns Regeneron 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"regeneron.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about Regeneron 10-Q

When did Regeneron file its latest 10-Q?
Regeneron filed its latest 10-Q (Quarter ended Sep 30, 2026) on Oct 30, 2026. The one before it was filed on Jul 30, 2026.
What did Regeneron disclose in its latest 10-Q?
From the filing dated Oct 30, 2026: Regeneron Enters Landmark April 2026 Agreements with U.S. Government Covering Pricing and Tariffs
What did Regeneron say on its recent earnings calls?
Q3 FY2026: Expanded Sanofi alliance adds four next-gen antibodies with $1B upfront (dated Oct 30, 2026).
Where can I read Regeneron's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/regn-20260930.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →